Quick summary
- GLP-1 drugs like Ozempic and wegovy can still lead to notable weight loss despite disruptions in usage.
- Research from Calibrate, involving over 6000 participants in the US (2021-2024), showed that:
– 73% experienced drug access issues (13+ weeks without medication).
– These participants lost an average of 14% body weight compared to the 17% weight loss among those with uninterrupted access.
- The program included health coaching, lifestyle lessons on diet/exercise, and optional GLP-1 medications for an additional fee.
- Findings were presented at the Endocrine Society’s annual meeting on July 14 in San Francisco.
- Experts suggest further research is needed to assess how coaching and lifestyle changes influenced outcomes. Some participants also took metformin (linked to minor weight loss effects).
Image Credit: Associated Press / Alamy
!campaign=RSS%7CNSNS&utmsource=NSNS&utmmedium=RSS&utm_content=home”>Read More